INTRODUCTION
Invasive fungal infections have become a challenging issue with regard to neutropenic patients. Because of delays in diagnosing such infections, they are frequently fatal. Sometimes they are only diagnosed at the autopsy. 1 Prolonged neutropenia is a major risk factor for invasive fungal infection. The incidence of invasive fungal infections ranges from 2% to 47%, depending on many other concomitant risk factors (e.g. the use of steroids or lymphoid malignancies). 2 In the early 1980s, many trials drew attention to the empirical and prophylactic application of antifungal drugs within such a scenario. In fact, amphotericin B deoxycholate (AmB-D) in the setting of persistent fever in neutropenic patients reduces the relative risk for documented invasive fungal infections by 50% to 80% and the overall mortality rate by 23% to 45%. 2 The use of AmB-D in these patients is, however, limited by the frequent induction of nephrotoxicity and by the undesirable infusion-related side effects such as fever, rigors and chills. Because of this adverse toxicity profile, AmB-D has been compared unfavorably with new amphotericin formulations and other antifungal drugs. 2 In the late 1990s, liposomal amphotericin B (L-AmB) emerged as a new option for the treatment for persistent fever in neutropenic patients by reducing the frequency of proven breakthrough fungal infections, with lower infusion-related toxic reactions and also reduced nephrotoxicity, [2] [3] [4] in comparison with AmB-D. Recently, other antifungal drugs, such as new triazoles and caspofungin, have emerged as promising agents for the prevention of invasive fungal infections in persistently febrile neutropenic patients. [2] [3] [4] In fact, in a comparative trial, voriconazole, a second-generation triazole, proved to be a suitable alternative to amphotericin B preparations. 4 The major inconvenience of these new antifungal drugs, however, is their higher cost, which may seriously hamper their use in underdeveloped countries.
Recently, a small randomized trial comparing continuous intravenous versus four-hour infusion of AmB-D showed a lower incidence of infusion related events and nephrotoxicity among the patients who received continuous intravenous infusion. 5 Following the publication of these results, we also started to use AmB-D in the form of continuous 24-hour infusion. Here, we report on our preliminary experience with continuous infusion of AmB-D at our center, in terms of its efficacy and toxicity.
OBJECTIVE
To evaluate the efficacy, safety and toxicity of continuous infusion of AmB-D in febrile patients with neutropenia consequent to undergoing chemotherapy for hematological malignancies. 
PATIENTS AND METHODS

RESULTS:
The median dose of AmB-D was 0.84 mg/kg/day (0.33 to 2.30 mg/kg/day). Concomitant use of nephrotoxic medications occurred in 92% of the cycles. Nephrotoxicity occurred in 30.76% of the cycles, hypokalemia in 16.67%, hepatotoxicity in 30% and adverse infusion-related events in 23%. All patients survived for at least seven days after starting continuous infusion of AmB-D, and clinical resolution occurred in 76% of the cycles.
CONCLUSIONS:
Continuous infusion of AmB-D can be used in our Institution as an alternative to the more toxic four-hour infusion of AmB-D and possibly also as an alternative to the more expensive liposomal formulations of the drug. Three of the initial 15 patients were excluded from the analyses. Two of these had another antifungal agent administered together with the continuous infusion of AmB-D, and the other had not received previous systemic chemotherapy. One patient received two cycles of continuous infusion of AmB-D and was analyzed twice as each admission was considered as a separate event. A total of 13 procedures of continuous infusion of AmB-D were therefore administered.
The records of all 12 patients were retrospectively reviewed. The presence of toxicity and absence of breakthrough infection was verified according to the following criteria proposed by Walsh: 4 • Creatinine level increased to 1.5 times baseline value; • Hypokalemia ≤ 2.5 mmol/l; • Hypomagnesemia ≤ 0.6 mmol/l; • Increased bilirubin levels; • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level of more than five times baseline values, if these values were greater than the reference range. Hepatotoxicity was also deemed to be present when AST or ALT was three times more than baseline, if the baseline was between two and five times the normal range. On the other hand, if the baseline was between 5 and 10 times the normal range, AST or ALT only had to reach twice the baseline value for hepatotoxicity to be deemed present. The baseline values were considered to be the laboratory values obtained immediately before the continuous infusion of AmB-D was started.
Because of drug stability concerns, the total dose of AmB-D required (mg/kg/day) was divided into four doses, and each of these was given as a 6-hour infusion procedure. Each quarter of the total dose was thus given in the form of 250 ml of 5% glucose solution, without any additives.
The infusion-related toxic reactions were retrospectively estimated from the frequency with which our Institution's protocol for the treatment of fever, chills and rigors secondary to AmB-D infusion was utilized (i.e. considering any use of acetaminophen, diphenhydramine, steroids or meperidine during the period of continuous infusion of AmB-D). Concomitant use of other nephrotoxic drugs was defined as the simultaneous use of aminoglycoside, foscarnet or cyclosporin.
The degree of certainty of the diagnosis of fungal infection was defined according to the Walsh criteria: 
RESULTS
Among the patients included, 76.9%
were female, the mean age was 36.23 years and 61.5% had acute myelogenous leukemia as the diagnosis (Table 1) .
In 61.5% of the cases, the site of fungal infection could not be determined. In 53.8%, the presumptive diagnosis was based on radiographic findings, while bronchoalveolar lavage/sputum was positive in 15.4%, and positive blood culture occurred in only 7.7% of the cases ( Table 1) .
The mean length of time since the previous broad-spectrum antibacterial therapy was 18.23 days, and a mean of 3.84 antibiotics had previously been administered to each patient. Prophylactic fluconazole had been prescribed for 61.5% of the patients. The mean rate for the continuous infusion of AmB-D was 0.84 mg/kg/day (range from 0.33 to 2.30 mg/kg/day).
In 30.76% of the patients, the creatinine level increased to 1.5 times baseline, but 92.4% of them were also taking other nephrotoxic drugs (aminoglycoside in all cases). Adverse infusion-related events were present in 23% of the cycles and hepatotoxicity in 30% of them (Table 2) .
With regard to the efficacy criteria, 100% of the patients were alive one week after continuous infusion of AmB-D started. Three fungal infections were documented, and two of these (66.60%) resolved completely. Breakthrough fungal infection was absent in 92.30% of the cases. There was no discontinuation of the drug due to toxicity or absence of efficacy, nor was there any need for association with another antifungal agent. In 76.92% of the cases, the fever resolved while the patient was still in the neutropenic period (Table 3) . DISCUSSION Fungal infections within a scenario of neutropenia are always a challenge in caring for cancer patients, especially after chemotherapy. Because of the potential for high morbidity and mortality, any delay in diagnosing such infections may be fatal. Invasive fungal infection rates have ranged from 3% to 42% in patients with acute myelogenous leukemia treated with cytarabine and anthracyclinebased chemotherapeutic regimens, and the mortality rates may reach 6% to 60%. 6 During the last twenty years many different drugs have been developed to ameliorate and control fungal infections. On the other hand, economic issues related to this new formulations have been voiced. In the 1990s, L-AmB emerged as an alternative for the treatment of febrile neutropenic patients and was shown to be as effective as AmB-D and to cause lower infusion-related toxicity, less nephrotoxicity and fewer breakthrough fungal infections. 3 Recently, a randomized trial was reported in which, despite the high cost of L-AmB, the pharmacoeconomic issues favored the use of L-AmB for patients at a high risk of developing renal failure. It was also suggested that to change patients from AmB-D to L-AmB after high levels of toxicity have developed may not be the most cost-effective strategy. Although some studies have supported the use of L-AmB as a standard antifungal agent, on the basis of its efficacy and from cost effectiveness analyses, many institutions have to limit their routine use of this practice because of the very high cost of L-AmB. Interestingly, in a recent randomized controlled trial that compared the use of 4 or 24-hour infusion of AmB-D, the 24-hour infusion of AmB-D reduced nephrotoxicity and the side effects related to infusion, without increased mortality. 5 Continuous infusion of AmB-D therefore emerges as an interesting investigational alternative in the recent literature because of its promisingly low toxicity profile, effective antifungal activity and significantly lower cost. In fact, one milligram of L-AmB is about 35 times more expensive than one milligram of AmB-D (data not presented).
In our observational study, continuous infusion of AmB-D produced nephrotoxicity in 30.75% of the cycles, which was similar to the rate reported by Eriksson 5 (33%) with 24 hour infusion of AmB-D and Walsh (29.40%) with L-AmB. 3 These results represent a marked reduction in comparison with classic AmB-D therapy (Table 2) . Hypokalemia seemed to be higher in our study, maybe due to the higher rate of concomitant use of other nephrotoxic drugs. Therefore, we strongly recommend potassium and magnesium supplementation, even after completing the therapy of continuous infusion of AmB-D. Hepatotoxicity was also a concern. Interestingly, one of the two patients who had the most marked increase in the liver function tests had also had a course of fluconazole treatment lasting 59 days, prior to the continuous infusion of AmB-D. The continuous infusion of AmB-D used in our study was effective. In fact, in this small observational study, there were no deaths during the first seven days after starting the continuous infusion of AmB-D, there was no discontinuation due to lack of efficacy or extreme toxicity, and no other concomitant antifungal drugs were necessary. Table 3 presents a comparison between our data and results in the literature for AmB-D and L-AmB.
Although this was a retrospective study with a small number of patients, the results are interesting and very encouraging for us to start planning a prospective trial of continuous infusion of AmB-D in neutropenic patients with dose escalation allied to pharmacoeconomic considerations.
CONCLUSION
Continuous infusion of AmB-D in our small retrospective experience was safe, cheap and effective. Further improvement in the outcomes from treating patients using continuous infusion of AmB-D may be possible with dose escalation. Prospective studies are needed in order to further explore the favorable pharmacoeconomic profile of this drug, and to reproduce our preliminary experience with this drug.
